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Shifts of Faecal Microbiota During 
Sporadic Colorectal Carcinogenesis
Giorgia Mori1, Simone Rampelli  2, Beatrice Silvia Orena1, Claudia Rengucci3, Giulia De Maio3, 
Giulia Barbieri1, Alessandro Passardi4, Andrea Casadei Gardini  4, Giovanni Luca Frassineti4, 
Stefano Gaiarsa5,6, Alessandra M. Albertini1, Guglielmina Nadia Ranzani1, Daniele Calistri3 & 
Maria Rosalia Pasca  1
Gut microbiota has been implicated in the etiopathogenesis of colorectal cancer. The development of 
colorectal cancer is a multistep process by which healthy epithelium slowly develops into preneoplastic 
lesions, which in turn progress into malignant carcinomas over time. In particular, sporadic colorectal 
cancers can arise from adenomas (about 85% of cases) or serrated polyps through the “adenoma-
carcinoma” or the “serrated polyp-carcinoma” sequences, respectively. In this study, we performed 
16 S rRNA gene sequencing of bacterial DNA extracted from faecal samples to compare the microbiota 
of healthy subjects and patients with different preneoplastic and neoplastic lesions. We identified 
putative microbial biomarkers associated with stage-specific progression of colorectal cancer. In 
particular, bacteria belonging to the Firmicutes and Actinobacteria phyla, as well as members of the 
Lachnospiraceae family, proved to be specific of the faecal microbiota of patients with preneoplastic 
lesions, including adenomas and hyperplastic polyps. On the other hand, two families of the 
Proteobacteria phylum, Alcaligeneaceae and Enterobacteriaceae, with Sutterella and Escherichia/
Shigella being the most representative genera, appeared to be associated with malignancy. These 
findings, once confirmed on larger cohorts of patients, can represent an important step towards the 
development of more effective diagnostic strategies.
Colorectal cancer (CRC) is one of the leading causes of cancer related mortality globally, accounting for about 1.2 
million new cases and 690.000 deaths per year1,2. CRC is the third most common cancer in men and the second 
in women; its incidence is rising rapidly in many low-income and middle-income countries, while it is stable in 
more economically developed countries1,2.
CRC arises from a multistep process by which healthy gut epithelium slowly develops into preneoplas-
tic lesions, which in turn progress into malignant carcinomas3,4. Most sporadic CRCs follow the conventional 
“adenoma-carcinoma” sequence, associated with specific mutations occurring at specific progression stages2,3. 
In particular, about 85% of CRCs develop from a benign adenomatous polyp where an APC gene mutation is 
the first pathogenic event5–10. Specific adenomas’ features, such as size and histology, allow adenomas’ classifica-
tion as low- or high-risk adenomas, based on the patients’ likelihood of developing advanced neoplasia during 
surveillance3,11. Recently, molecular advances have identified an alternative pathway of colorectal carcinogenesis 
involving BRAF gene mutations and CpG islands’ hypermethylation. This pathway characterizes the “serrated 
polyp-carcinoma” sequence in which serrated polyps are the precursor lesion of CRC. Serrated polyps form a het-
erogeneous group of lesions that includes hyperplastic polyps, a tiny percentage of which progress to malignant 
cancer12–14.
The formation of intestinal preneoplastic lesions and carcinomas are associated with several risk factors, where 
microbiota dysbiosis (the alteration of the normal microbial community) is one of the most relevant15–17.
The microbiota is a complex community of microorganisms that coexist in close association with the host18. At 
present, there is no consensus on the composition of the gut microbiota in preneoplastic lesions or CRC. However, 
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some bacterial species such as Streptococcus bovis, Bacteroides fragilis, Enterococcus faecalis, Fusobacterium spp., 
and Escherichia coli, have been correlated with CRC carcinogenesis16,19. Gut microbiota could induce CRC car-
cinogenesis through several mechanisms, including: genotoxin production, modulation of host defences and 
inflammation pathways, oxidative stress induction and anti-oxidative defence regulation. These mechanisms can 
lead to genomic instability and epithelial cell proliferation, both underlying colorectal carcinogenic process11.
In order to explain how gut microbiota could affect the development of CRC, the “driver-passenger” theory 
was proposed16. This model states that some gut bacteria, called “drivers”, induce epithelial DNA damage and 
cause inflammation by increasing cell proliferation and/or by producing genotoxic substances that contribute to 
the accumulation of mutations during tumorigenesis. These changes facilitate the gradual replacement of driver 
bacteria by “passengers”, with a growth advantage in the tumour microenvironment16. CRC progression may be 
either suppressed by probiotic species or promoted by pathogenic microorganisms. Because of their temporal 
association with the gut mucosa, driver and passenger bacteria have different roles in CRC progression, but each 
of them causes alterations during carcinogenesis. Most of the “driver” bacteria may be underrepresented in the 
adenoma-carcinoma sequence, nonetheless their presence is enough to induce cancerogenesis16,20.
The characterization of the microorganisms participating in the genesis and progression of CRC could lead to 
the prediction of the evolution of pre-cancerous lesions by monitoring the absence of protective bacteria or the 
presence of possible drivers. Nakatsu and colleagues21 tried to identify microbes with potential causative roles in 
adenoma-carcinoma sequence performing 16 S rRNA gene sequencing on normal mucosae, adenomatous and 
malignant lesions. In particular, they found a specific enrichment of Fusobacterium in CRC lesions and a progres-
sive increasing abundance of B. fragilis and Granulicatella along the adenoma-carcinoma sequence21.
Aim of this study was to search for specific microbial patterns that could potentially be used as biomarkers 
of sporadic CRC carcinogenesis. Accordingly, we analysed and compared the faecal microbiota from healthy 
controls and from patients with either hyperplastic polyps, low-risk adenomas, high-risk adenomas or adenocar-
cinomas. Moreover, patients with adenocarcinomas who had received chemotherapy and/or radiotherapy were 
also investigated in order to assess the influence of treatments on gut microbiota composition.
Results
Clinical features of patients. All subjects enrolled in this study had undergone colonoscopy in order to 
assess the possible presence of colorectal lesions (Table S1). Subjects with negative colonoscopy were recruited as 
controls (healthy group). The study population (92 individuals, average age = 61.59) was composed of 6 groups: 
healthy (H = 18; average age = 58.16), hyperplastic polyps (HP = 14; average age = 59.42), low-risk adeno-
mas (LRA = 18; average age = 56.88), high-risk adenomas (HRA = 21; average age = 60.76), adenocarcinomas 
(ADK = 8; average age = 67.37) and a last group composed of patients with ADK who received chemotherapy 
and/or radiotherapy treatment (ADK-T = 13; average age = 67) (Table S1).
All clinical data are reported in Table S1, including localisation of colonic lesions and possible additional 
comorbidities.
Richness analysis. Illumina 16S rRNA sequencing of the DNA extracted from the 92 faecal samples 
produced a total of 11.087.753 filtered reads with an average of 120.519 sequences per sample (range: 13.616–
442.049). In total, 79.705 operational taxonomic units (OTUs) were delineated at a 97% similarity level.
Several different metrics were used to calculate α-diversity, including the Chao1 index for microbial richness, 
OTU species count, and phylogenetic diversity. All measures indicated a comparable microbial richness within 
the six groups (Fig. 1, Kruskal-Wallis test, P > 0.05).
Main bacterial taxa associated with preneoplastic/neoplastic lesions. Among the identified bac-
terial OTUs, here we present the most interesting taxa. The P-values assigned to each taxa (phylum/family/genus) 
refer to its significant contribution in every stage of the CRC progression (Figs S2, S3, S4).
Nineteen phyla were detected in patients with preneoplastic/neoplastic lesions and 18 phyla were detected 
in healthy subjects. In all groups, the five most abundant phyla were the following: Firmicutes, Bacteroidetes, 
Actinobacteria, Proteobacteria, and Verrucomicrobia (Figs S1; 2).
Figure 1. Evaluation of α-diversity in the 5 groups of patients and controls. (A) Chao1 measure of microbial 
richness; (B) Observed OTUs; (C) Phylogenetic diversity.
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The bacterial flora analysis showed that Firmicutes was the most predominant phylum, contributing with the 
lowest values in ADK samples (39.65% and 36.49% in ADK and ADK-T, respectively). In healthy subjects and in 
patients with adenomas and hyperplastic polyps, the abundance of Firmicutes was higher, ranging from 47.14% 
(LRA) to 62.19% (HP) and 63.71% (HRA) (Figs 2; S2; P = 0.009).
The second most dominant phylum was Bacteroidetes with the highest contribution in ADK samples (50.73% 
and 39.60% in ADK and ADK-T, respectively). A lower contribution was found in healthy subjects (37.13%). In 
HP, LRA and HRA groups, Bacteroidetes was present at 26.8%, 40.33% and 27.56%, respectively. Indeed, these 
differences were not significant (Figs 2; S2; P = 0.13).
Proteobacteria was the third most abundant phylum with significant richness in ADK samples (5.4% and 
19.71% in ADK and ADK-T, respectively). The lowest contribution of this phylum was shown by healthy subjects 
(1.6%). In the other groups, Proteobacteria phylum was found with the following abundances: 6.57% in HP, 2.83% 
in LRA and 4.1% in HRA (Figs 2; S2; P value = 0.005).
On the contrary, Actinobacteria showed their lowest abundance in ADK patients (1.26% and 0.66% in ADK 
and ADK-T, respectively) and their highest abundance in H (2.31%), LRA (5.31%) and HP (2.8%) samples. This 
observation is supported by a P value of 0.06 (Figs 2; S2), suggesting a slight trend of increase towards benign 
lesions and healthy conditions.
Although results were not statistically significant, Verrucomicrobia showed the lowest abundance in ADK 
samples (0.47% and 1.45% in ADK and ADK-T, respectively) and the highest one in LRA patients (3.3%) (Figs 2; 
S2; P value = 0.9).
Among the poorly represented phyla, Fusobacteria showed low levels in LRA (0.06%) and healthy subjects 
(0.04%); they were almost absent in HP patients (0.007%) and poorly present in ADK-T group (0.03%), as well 
as in HRA and ADK samples (0.14% and 0.11%, respectively). In the same way, some authors22,23 observed no 
significant differences in the abundance of Fusobacterium, while other authors reported a positive correlation 
with CRC21,24–26.
More than 140 families and 460 genera were identified in the 92 samples.
Among the identified families, the abundance of Lachnospiraceae proved to be quite low in ADK and ADK-T 
samples (14.2% and 14.6%, respectively) (Fig. S3; P value = 0.017). This finding was confirmed by the results 
obtained at the genus level; the genera Blautia (P = 0.01) and Eubacterium hallii group (P = 0.01), both belonging 
to the Lachnospiraceae family, were also poorly represented in ADK and ADK-T samples (Fig. S4). The same 
behaviour was followed by other genera, belonging to the Lachnospiraceae family. The relative abundances of 
these genera, including Roseburia, Dorea, Pseudobutyrivibrio, Anaerostipes, Coprococcus, and Fusicatenibacter, 
were characterized by different levels of significativity (P values in Fig. S4). On the contrary, Lachnospiraceae 
family was mainly found in HRA and HP samples (31.7% and 29.8%, respectively) (Fig. S4; P value = 0.017).
Figure 2. Relative abundance of the main bacterial phyla in faecal microbiota of 7 groups of subjects. 
Histograms based on the proportion of OTUs per average of each group.
www.nature.com/scientificreports/
4ScIEntIfIc REPORTS |  (2018) 8:10329  | DOI:10.1038/s41598-018-28671-9
Similarly to Lachnospiraceae, but with data not supported by a strong statistical evidence, Erysipelotrichaceae 
family was mostly abundant in HRA and HP patients (2% and 1.8%, respectively) (Fig. S4; P value = 0.18).
Structural comparison of gut microbiota between healthy subjects and patients with prene-
oplastic/neoplastic lesions. Statistical analyses were performed in order to compare the overall struc-
ture of faecal microbiota of all considered groups. Wilcoxon non parametric signed-rank test highlighted an 
enrichment of Proteobacteria phylum in both ADK (P = 0.008) and ADK-T (P = 0.00004) samples (Table 1). In 
ADK samples, this result was confirmed by an increment in Enterobacteriaceae (P = 0.008) and Alcaligenaceae 
(P = 0.001) families, as well as in Escherichia-Shigella (P = 0.007) and Sutterella (P = 0.001) genera. The abun-
dance of Proteobacteria phylum (P = 0.00004) in ADK-T was remarkably higher than in the other taxa, but there 
was not a corresponding increment at the family or genus level (Table 1).
The Porphyromonadaceae (P = 0.004) and Prevotellaceae (P = 0.009) (Table 1) families were also highly abun-
dant in ADK patients.
In ADK and ADK-T patients, we observed a significant low abundance of genera belonging to the 
Lachnospiraceae family, such as Anaerostipes, Dorea, Fusicatenibacter and [Eubacterium] halii group. ADK-T 
patients were also characterized by a significant low presence of members belonging to the Actinobacteria phy-
lum (Table 1).
By Wilcoxon test, no significant differences were observed comparing the faecal microbiome of LRA to that 
of H subjects (data not shown).
Interestingly, HRA patient samples were featured by an increment of Erysipelotrichaceae family (P = 0.0008) 
and a significant presence of Blautia genus (P = 0.007), belonging to Lachnospiraceae family (Table 1).
Finally, in HP patients there was the lowest contribution of Prevotella genus compared to healthy subjects 
(4.2 versus 0.0007; P = 0.001). In order to better understand this result, the relative abundance of Prevotella 
in each of our patients and controls was considered (Table S2). However, the high presence of Prevotella in 
some samples (relative abundance >10%) did not appear to be related to any clinical feature. The presence 
of Prevotella in gut microbiota is commonly associated with a diet rich in carbohydrates and simple sugars. 
Moreover, Prevotella is a well-known dietary fiber fermenter, being quite abundant in some populations such as 
Hadza hunter-gatherers27,28. Moreover, Prevotella genus is involved in the production of short chain fatty acids 
(SCFAs), mainly acetate, the amount and proportion of which has been reported to be biologically relevant29,30. 
Unfortunately, information about patients’ diet was not available. Consequently, we could only hypothesize that 
the habitual diet of subjects showing an increase in Prevotella genus is responsible for its high presence, particu-
larly in those samples in which Prevotella contribution is significantly high, such as: H3, H11 and H14 (53.2%, 
Observed differences in microbiome of ADK-T samples
Healthy ± SEM ADK-T ± SEM P value
Phylum: Actinobacteria 2.3 ± 0.6 0.7 ± 0.2 0.004
Phylum: Proteobacteria 1.6 ± 0.6 19.7 ± 6.6 0.00004
Phylum: Unassigned 0.9 ± 0.1 1.3 ± 1.1 0.003
Genus: Dorea 0.8 ± 0.1 0.4 ± 0.1 0.006
Genus: Fusicatenibacter 1.0 ± 0.3 0.4 ± 0.3 0.008
Genus: [Eubacterium] halii group 1.3 ± 0.2 0.5 ± 0.2 0.0007
Observed differences in microbiome of ADK samples
Healthy ± SEM ADK ± SEM P value
Phylum: Proteobacteria 1.6 ± 0.6 5.4 ± 1.3 0.008
Family: Porphyromonadaceae 1.7 ± 0.3 4.6 ± 1.0 0.004
Family: Prevotellaceae 5.0 ± 3.1 8.1 ± 2.7 0.009
Family: Alcaligenaceae 0.2 ± 0.1 1.5 ± 0.6 0.001
Family: Enterobacteriaceae 0.9 ± 0.4 2.8 ± 0.8 0.008
Genus: Anaerostipes 0.8 ± 0.2 0.2 ± 0.1 0.001
Genus: Sutterella 0.08 ± 0.04 0.7 ± 0.2 0.001
Genus: Escherichia-Shigella 0.8 ± 0.3 2.7 ± 0.8 0.007
Observed differences in microbiome of HRA samples
Healthy ± SEM HRA ± SEM P value
Family: Erysipelotrichaceae 0.6 ± 0.2 2.0 ± 0.5 0.0008
Genus: Blautia 6.7 ± 2.9 10.8 ± 2.2 0.007
Observed differences in microbiome of HP samples
Healthy ± SEM HP ± SEM P value
Genus: Prevotella 4.2 ± 3.0 0.0007 ± 0.0004 0.001
Table 1. Wilcoxon Test: comparison of faecal microbiome from healthy subjects with that of the patients’ 
groups (HP, HRA, ADK and ADK-T). Each group of patients was compared with the group of healthy subjects. 
Significant P-values are reported. No statistically significant differences were detected between LRA patients 
and healthy subjects (data not reported).
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11.9% and 10.7%, respectively); LRA16 and LRA18 (23.4% and 19.6%); HRA7 and ADK6 (35.8% and 10.7%) 
(Table S2). It would be extremely helpful, in addition to the clinical features of patients, to have diet information 
in order to understand the real contribution of Prevotella.
The principal component analysis (PCoA) based on Unweighted UniFrac distances revealed the formation of 
3 different clusters: the first one comprising ADK and ADK-T patients; the second one with HP and HRA indi-
viduals; the last one composed of H subjects and LRA patients (Fig. 3A). The superimposition of bacterial genera 
on the PCoA plot identified the genera involved in these separations. In particular, in ADK and ADK-T patients, 
the main genera involved were Sutterella, Ruminococcaceae UCG-002, Parabacteroides and Bacteroides. HP and 
HRA individuals showed a higher contribuition of bacteria, such as Faecalibacterium, Dorea, Pseudobutyrivibrio, 
Eubacterium hallii group, Ruminococcus, Fusicatenibacter and Anaerostipes. The Erysipelotrichaceae family was 
highly represented in these groups of patients, thus confirming the result obtained with the Wilcoxon test for the 
HRA group (Table 1). In H and LRA clusters, the discriminant genera were represented by Bifidobacterium and 
Akkermansia (Fig. 3).
The PCoA quantitative Weighted UniFrac analysis showed that ADK patients are separated from all the other 
groups (Fig. 4A), with Sutterella, Parabacteroides and Bacteroides being the main discriminant genera correlated 
with this separation. Genera Lachnobacterium, Blautia, Anaerostipes, Dorea and Eubacterium hallii group were 
prevalent in H, HP, LRA, HRA and ADK-T. In agreement with above reported data, Erysipelotricaceae family was 
present in this last cluster (Fig. 4B).
Diversity analysis. The variation of the Weighted UniFrac MDS3 coordinates between the study groups 
are reported in Fig. 5. The data were comparable for all the groups except for ADK-T, showing the highest var-
iability (range of microbial diversity: 0.3–1). This result is in agreement with that obtained with the Wilcoxon 
test in which the significant presence of Proteobacteria was not associated with a significant abundance of spe-
cific genera or families (Table 1). Oppositely, the faecal microbiota of ADK-T group was composed of many 
families and genera belonging to Proteobacteria, such as Alcaligenaceae, Comamonadaceae, Neisseriaceae, 
Desulfovibrionaceae, Enterobacteriaceae, Moraxellaceae, Citrobacter, Enterobacter, Legionella, Haemophilus, 
Figure 3. Bacterial taxa differentiate 3 clusters: ADK and ADK patients; HP and HRA patients; LRA patients 
and H subjects. (A) PCoA based on Unweighted UniFrac distances; (B) Superimposition of bacterial genera on 
the PCoA plot.
Figure 4. Bacterial taxa abundance differentiates ADK from HP, LRA, HRA and ADK-T patients and healthy 
subjects. (A) PCoA based on Weighted UniFrac distances; (B) Superimposition of microbial genera on the 
PCoA plot.
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Acinetobacter, Pseudomonas, Stenotrophomonas, Parasutterella, Moraxella, Aquabacterium, Comamonas, Delftia, 
Pelomonas, Bilophila, Desulfovibrio, Succinivibrio and Cloacibacillus, all present at very low abundance. Most of 
these genera are related to nosocomial infections, one of the possible side effects of chemotherapy and/or radio-
therapy treatments. Of relevance, ADK-T patients were all characterized by the presence of Proteobacteria, but 
each of the patients had its specific faecal microbiota profile, probably due to a growth advantage of opportunistic 
bacteria. Therefore, the absence of a common microbiota response to the treatments suggests that each patient 
reacts to chemotherapy and/or radiotherapy in an individual way.
Beta diversity is represented and P values are calculated with Wilcoxon Test. Significant results are here 
reported: (HRA, ADK) vs (ADK-T) = 2.568023e-11; (Healthy, HP, LRA) vs (ADK-T) = 0.0002791042; (Healthy, 
HP, LRA) vs (HRA, ADK) = 8.430536e-10.
Discussion
The gut microbiota is composed by a complex community of microorganisms with a critical role in human phys-
iology and metabolism31–34. These microorganisms are considered to be one of the main factors influencing the 
pathogenesis of CRC35–39. Differences in the faecal microbiota composition of patients with CRCs or adenomas 
have been investigated, but available information is insufficient to build a comprehensive picture40–43.
In this study, the microbiota composition of LRA, HRA, ADK, ADK-T and HP groups was investigated from 
faecal samples, using healthy subjects (H) as a control (Table S1).
The average age of our ADK group is higher than those of the preneoplastic groups. This observation is 
in agreement with the increase in CRC incidence with age44: as reported in the AIOM (Italian Association of 
Medical Oncology) Guidelines44, colorectal cancer incidence increases from 8%-4% in men and women younger 
than 50 years of age, to 14%-17% in subjects older than 70 years of age. Under healthy conditions, the gut micro-
biota remains relatively stable throughout adulthood. However, the ageing process affects the composition of the 
microbiota and is associated with loss in microbial diversity and richness45. As the average age of our ADK and 
ADK-T groups is only 5,78–5,41 years higher than the average age of all the subjects analysed in this study, and 
since the α-diversity analysis revealed a comparable microbial richness within the six groups analysed (Fig. 1), we 
can hypothesize that the age difference among study groups did not influence our analysis. Moreover, a compar-
ative study addressing differences in gut microbiota along the life-span suggested that age-related changes occur 
at approximately 75–80 years46.
The study of the composition of the faecal bacterial community can be affected by various factors includ-
ing experimental design and technical procedures (e.g. collection and storage of faecal samples; bacterial DNA 
extraction; sequencing technology). The methods employed in this work were selected according to protocols 
that were previously reported to allow a reliable analysis of the faecal microbiota. Samples freezing prior to DNA 
extraction was earlier shown to result in minimal and non-significant differences in faecal microbiota composi-
tion as compared to using freshly collected samples47,48. Preservation of the integrity of the faecal microbiota by 
sample freezing was confirmed by using different sequencing platforms (Roche 454 pyrosequencing, Illumina 
MiSeq and Ion Torrent)47–49 and was shown to be independent of the freezing speed48 and of the length of the 
storage period47. In addition, in agreement with recent observations49, the use of QIAamp DNA stool kit (Qiagen, 
Netherlands) allowed extraction of high quality DNA.
In this study, we identified microbial associations specific for each group of samples (H, LRA, HRA, ADK, 
ADK-T and HP); specific microorganisms might represent potential biomarkers of sporadic CRC neoplastic 
progression (summarised in Fig. 6 and Table 2).
Firmicutes, Bacteroidetes, Actinobacteria and Proteobacteria were the dominant phyla in healthy controls, 
in agreement with previous studies on gut microflora18. A large decrease in Firmicutes and Actinobacteria with 
concomitant relative expansion of Proteobacteria was observed in patients with ADK. In general, subjects with 
preneoplastic/neoplastic lesions showed a decrease in the Firmicutes/Bacteroidetes ratio, which might be consid-
ered an important marker for intestinal dysbiosis (Figs 2; 6; S2). LRA, HRA and HP samples were characterized 
by the presence of bacteria belonging to Lachnospiraceae family that, on the contrary, decreased or disappeared 
in ADK samples (Fig. 6; Table 2).
Schematic representation of CRC progression and associated faecal microorganisms. H = healthy epithelium; 
LRA = low-risk adenoma; HRA = high-risk adenoma; ADK = adenocarcinoma; ADK-T = adenocarcinoma 
treated with radio/chemotherapy; HP = hyperplastic polyps. Bacteria specifically identified in each stage of CRC 
Figure 5. Range of microbial diversity in the investigated groups.
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progression are indicated by also taking into account literature data. Green and red indicate protective and path-
ogenic bacteria, respectively.
As previously described, Actinobacteria and Firmicutes were the most abundant phyla in LRA, HRA and HP 
groups and decreased in ADK patients (Fig. S2). Similarly, Lachnospiraceae family, belonging to the Firmicutes 
phylum, was the most abundant in the same groups (Fig. S3). Further evaluating Lachnospiraceae family, 
Anaerostipes significantly decreased in ADK samples (Table 1). This finding is in agreement with previous studies 
comparing the faecal microbiota of healthy subjects with that of CRC and adenoma patients19,42.
Summarizing, Actinobacteria and Firmicutes phyla, as well as bacteria belonging to Lachnospiraceae family, 
could be considered as good biomarkers specific for H, LRA and HP. It is noteworthy that these three taxa are 
indicated in literature as bacteria with a putative protective action20,28,50,51.
Another possible biomarker of the same groups of patients is represented by Erysipelotrichaceae family, show-
ing its highest contribution in HP and HRA samples (Figs 3; 4; 6), while decreasing in abundance in ADK. The 
role of Erysipelotrichaceae in inflammation-related disorders of the gastrointestinal tract is known, being these 
bacteria abundant in the lumen of CRC patients25,52. In addition, high levels of Erysipelotrichaceae are related 
with obesity or, in general, with a high fat diet. Recently, in agreement with our results, Peters and collaborators42 
found an abundance of Erysipelotrichaceae family in conventional adenomas and in hyperplastic polyps (Fig. 6).
In our study, several genera proved to be overrepresented in ADK patients (Table 1; Figs 3; 4; 6). In particular, 
the faecal microbiota of ADK patients compared to healthy subjects was enriched in Porphyromonadaceae and 
Prevotellaceae families, in agreement with previous findings25.
Two families belonging to the Proteobacteria phylum, Alcaligeneaceae and Enterobacteriaceae, were domi-
nant in ADK group (Table 1; Figs 3; 4; 6). By considering the Alcaligeneaceae family, Sutterella proved to be the 
Figure 6. Putative faecal biomarkers of sporadic CRC cancerogenesis.
Phylum Family Genus Purported functions
Actinobacteria Protective action20
Firmicutes
Lachnospiraceae
Anaerostipes Butyrate producer; improve intestinal defense protecting the host49
Blautia Acetate producer; improve intestinal defense protecting the host27
Dorea Protective action27
Eubacterium hallii group Butyrate producer; Protective action51
Pseudobutyrivibrio Butyrate-producer28
Erysipelotrichaceae — Potential candidate in the aetiology and progression of colorectal cancer27
Bacteroidetes
Porphyromonadaceae — Pro-carcinogenic27,31
Prevotellaceae Pro-carcinogenic30
Proteobacteria
Enterobacteriaceae Escherichia-Sighella Genotoxin-producers; Pro- carcinogenic27
Alcaligenaceae Sutterella Frequently associated with human diseases33
Table 2. Putative microbial biomarkers identified in this study.
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most abundant genus (Table 1). Some authors reported that Sutterella genus includes commensal bacteria with 
pro-inflammatory capacities in the gut, proposing its role in the pathogenesis of inflammatory bowel diseases, as 
well as of some neurological disorders53.
Among the Enterobacteriaceae family, the most abundant genus appeared to be Escherichia/Shigella. The role 
of this genus in CRC progression is still under evaluation, being Escherichia/Shigella considered both as a driver 
and as a passenger16,54. In our study, Escherichia/Shigella was prevalent in the ADK group.
Regarding the ADK group, Alcaligenaceae and Enterobacteriaceae families, with their most representative 
genera (Sutterella and Escherichia/Shigella, respectively) could be consider as potential biomarkers of progression 
to malignancy.
In the ADK-T group, we found the highest diversity in microorganisms belonging to the Proteobacteria 
phylum (Citrobacter, Enterobacter, Legionella, Haemophilus, Acinetobacter, Pseudomonas, Stenotrophomonas, 
Parasutterella, Moraxella, Aquabacterium, Comamonas, Delftia, Pelomonas, Bilophila, Desulfovibrio, Succinivibrio, 
Cloacibacillus). This is in line with the possible presence of nosocomial infections caused by the treatments 
(chemotherapy and/or radiotherapy). Of relevance, ADK patients treated with chemotherapy and/or radiother-
apy were characterized by the absence of a specific faecal microbiota, suggesting heterogeneous and individual 
responses to the treatments. Some authors reported that chemotherapy and radiotherapy are associated with 
reduced diversity in gut microbiota and with changes in its composition55. Montassier and collaborators56 iden-
tified microbes that changed during chemotherapy independently from other additional factors; faecal samples 
collected after chemotherapy were characterized by an increase of Enterococcaceae and Enterobacteriaceae, and a 
decrease of Ruminococcaceae, Lachnospiraceae and Bifidobacterium57.
Recently, Sze and collaborators (2018)57 tested the composition of faecal microbiota before and after the treat-
ments for adenomas, advanced adenomas and carcinomas. The aim of these authors was to understand how faecal 
microbiota changes after a long period subsequent the treatment. The authors found that there were no significant 
differences between pre- and post-treatment samples from patients with adenoma and advanced adenoma; for 
carcinomas, not only changes were found in pre- versus post-treatment samples, but also these changes were 
toward a more normal microbiota57.
In our study, we investigated the gut microbiota composition of ADK-T group patients that were currently 
under treatment, finding that our ADK-T group was characterized by a change in the faecal microbiota, including 
an increased microbial diversity, likely due to nosocomial infections (Figs 5; 6). Accordingly, it was impossible to 
identify a microbial biomarker specific for this group of patients.
To the best of our knowledge, this is the first analysis to evaluate in parallel the faecal microbiota composition 
of healthy subjects and patients with ADK/ADK-T, LRA/HRA and HP.
In their work, Nakatsu and collaborators21 found different microbial associations in mucosal biopsy sam-
ples at each stage of adenoma-carcinoma sequence, whilst they did not investigate samples from serrated 
polyp-carcinoma sequence. As previously shown58, the microbiota composition of mucosal and faecal samples 
from CRC patients differs significantly. For example, in CRC mucosal samples Nakatsu and collaborators found 
an abundance of Fusobacterium, B. fragilis and Granulicatella. In our work, ADK samples were characterized by 
very low levels of Fusobacterium and Granulicatella (0.08% and 0.025%, respectively), even if this is the stage in 
which they are most abundant.
With this study, we compared the faecal microbiota composition of patients with preneoplastic and neoplastic 
lesions with that of healthy subjects and we identified specific microbial biomarkers associated with each carcino-
genic stage. Moreover, the contribution of chemoterapy/radiotherapy was investigated, highlighting the great 
abundance of opportunistic pathogens.
The identification of bacterial communities that are specific of preneoplastic/neoplastic lesions can be 
regarded as an important step towards the development of more effective diagnostic strategies. Additional work 
should be done not only by analysing patients at different risk of CRC progression over a prolonged period, but 
also a larger cohort of patients, mucosal tissues analysis and a metagenomic approach should be considered. In 
this way it would be possible to confirm the investigated potential biomarkers of CRC progression and their pos-
sible causative association with CRC carcinogenesis.
Methods
Study population and stool samples. For this study, we recruited patients diagnosed with hyperplastic 
polyps (HP), low-risk adenomas (LRA), high-risk adenomas (HRA) and adenocarcinomas (ADK).
All subjects were recruited at the Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) 
of Meldola (FC, Italy) between 2013 and 2015. Enrolled patients were a subgroup of the protocol IRSTB002, 
approved by the Ethic Committee of IRST - IRCCS AVR (25/10/2012, ver.1). All methods were performed in 
accordance with relevant guidelines and regulations and written informed consent was obtained from all patients. 
The Biosciences Laboratory of IRST, in collaboration with the Cancer Prevention Services of the Local Health 
Authority of Romagna (Forlì, Cesena and Ravenna, Italy), is responsible for identifying genetic factors involved 
in predisposition to cancer and for activating appropriate prevention strategies for individuals at risk. The individ-
uals who are candidates for genetic testing are essentially those with a suspected hereditary predisposition to the 
development of specific cancers (e.g.: Hereditary Breast and Ovarian Cancer, Hereditary diffuse gastric cancer, 
Li-Fraumeni Syndrome, Neurofibromatosis Type II and Lynch syndrome). None of the patients included in this 
study met the criteria for genetic counselling/ genetic testing: early-onset patients and subjects with family history 
of cancer were excluded from this analysis.
Eligible participants were individuals 40–80 years old who recently underwent colonoscopy. Hyperplastic 
polyps, adenomas, and adenocarcinomas were identified during colonoscopy and confirmed by the pathologist. 
Subjects with histologically confirmed normal biopsies were included in the control group (18 subjects).
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The results of endoscopic and histological examination were the following: 21 subjects were diagnosed with 
ADK, 21 with HRA, 18 with LRA, 14 with HP.
Preneoplastic lesions were classified as low- or high-risk according to National Comprehensive Cancer 
Network guidelines59. Briefly, LRA were defined as 1–2 adenomas with size <10 mm; HRA were indicated as 3 or 
more adenomas with size ≥10 mm.
Stool specimens were collected by each participant about 1–2 days before the bowel preparation for the colo-
noscopy examination. Faecal samples were immediately stored at 4 °C and brought to the Bioscience Laboratory 
of IRST (Meldola, Italy) within 24–48 h. The stool samples were suspended in Olson buffer (0.5 mol/L Tris HCl; 
0.15 mol/L EDTA, 10 mmol/L NaCl, PH = 9)60 and stored at −80 °C. An aliquot of each sample was shipped in 
dry ice within a time frame of 3 months to the Department of Biology and Biotechnology “Lazzaro Spallanzani” 
(University of Pavia, Italy) where it is stored at −80 °C until DNA extraction. All samples (included control sam-
ples) were processed in the same way.
Clinical data collection. Demographic information and clinic data are reported in Table S1. Moreover, the 
localization of colonic lesion for each patient is specified in Table S1. For each participant, data about comorbid-
ities were also recorded. Treatment with chemotherapy/radiotherapy was specifically assessed, given its possible 
interaction with gut microbiota.
Extraction of nucleic acids for microbiome analysis. DNA was extracted from faeces using QIAamp 
DNA stool kit (Qiagen, Netherlands) according to the specifications of the manufacturers. The V4 region of 16 
rRNA gene was amplified using the 515 F forward primer (GTGYCAGCMGCCGCGGTAA) and barcoded 806 R 
reverse primers (GGACTACNVGGGTWTCTAAT) as previously described61,62. Sequencing was performed on 
the Illumina MiSeq platform, and paired-end reads of 250b in length in each direction were generated producing 
a total of 11.087.753 filtered reads from 92 high-quality samples (6 samples were removed because of technical 
failures). The reads were pre-processed and analyzed with the Qiime pipeline for taxonomic composition, alpha 
diversity, and beta diversity analysis61,63. Alpha-diversity and rarefaction plots were computed on the normalized 
OTU table using three different metrics: PD whole tree, chao1 and observed species. Weighted and unweighted 
UniFrac distances were used to perform PCoA.
Biostatistics. The R packages Stats and Vegan (http://www.cran.r-project.org/package=vegan) were used 
to perform statistical analysis. In particular, to compare gut microbiome structure among different groups for α 
and β diversity, we used a Wilcoxon-signed rank test and a Kruskal-Wallis test. Data separation in the PCoA was 
tested using a permutation test with pseudo F-ratios (function Adonis in the Vegan package). Significant differ-
ences in phylum or family or genus-level abundance between groups, were assessed by Mann–Whitney U-tests, 
and corrected for multiple comparisons using the Benjamini–Hochberg method when appropriate (Table 1). 
False discovery rate (FDR) <0.05 was considered as statistically significant.
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